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Besides the structural function in proteins, aromatic 
amino acids are precursors of many important biologi-
cal compounds essential for normal functioning of the 
human organism. Many of these compounds may be 
used as markers for identification of specific pathologi-
cal states. Comprehensive knowledge about the metabo-
lism of aromatic amino acids and mechanisms of action 
of their metabolites made it possible to develop effec-
tive treatments for many disorders. However, it should 
not be forgotten that in some pathological conditions, 
these compounds could not only be involved in the 
pathogenesis of many disease entities but could also be 
used as an important tool in prediction of many diseas-
es. This paper contains a review of published literature 
on aromatic amino acids in the context of physiological 
processes of the human body and chosen social disor-
ders, such as cancers; psychiatric disorders: depression, 
anxiety states, schizophrenia, bipolar affective disorders; 
neurodegenerative, and cardiovascular diseases; chronic 
kidney insufficiency or diabetes.
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THe signifiCanCe of TyRosine and iTs MeTaBoliTes 
in pHysiology and paTHology
Besides the structural function in proteins, aromatic 
amino acids are precursors of many important bio-
logical compounds, such as neurotransmitters and hor-
mones, in the human organism. Catecholic amines, such 
as dopamine, norepinephrine, and epinephrine are syn-
thesized from tyrosine (Tyr). In the first step, l-DOPA 
(L-3,4-dihydroxyphenylalanine) is formed as a result of 
tyrosine hydroxylase action (EC 1.14.16.2; HT). Then, 
l-DOPA undergoes fast decarboxylation to dopamine 
by aromatic l-amino acid decarboxylase (EC 4.1.1.28; 
LAAD) (Hadjiconstantinou & Neff, 2008). This process 
occurs in neurons of substantia nigra, from which the 
neurotransmitter is transported to striatum and then re-
leased on nerve endings. In Parkinson’s disease, neurons 
of the nigrostriatal pathway undergo degeneration that 
results in the impairment of dopaminergic conduction 
manifested by tremors at rest and bradykinesia (slow-
ness of movements). After administration of l-DOPA 
to patients, the compound crosses the blood-brain bor-
der, elevates the concentration of dopamine in brain, 
and alleviates disease symptoms (Tedroff, 1999; Row-
land, 2005). Oxidation stress and subsequent oxidation 
of proteins, lipids and nucleic acids also play a significant 
role in the damage of dopaminergic neurons. Dopamine 
is also produced in chromaffin cells of the adrenal me-
dulla where it is later converted first to norepinephrine 
by dopamine β-hydroxylase (EC 1.14.17.1; DBH), then 
to epinephrine by phenylalanine-N-methyltransferase 
(EC 2.1.1.28; PNMT). Blood flow-pressure is regulated 
by catecholamines generated in the adrenal medulla. 
They are released during stress situations. Increased re-
lease of catecholamines into the circulation was observed 
in neoplasms originating from phaeochromocytoma and 
in undifferentiated neuroblastic cells of the sympathetic 
system in ganglia and the adrenal medulla (neuroblasto-
ma, ganglioneuroma). The increase in l-DOPA, norepi-
nephrine and chromogranin A concentration in plasma 
was observed in phaeochromocytoma, which can be in-
dicative of malignancy of this neoplasm. However, a de-
crease in norepinephrine and epinephrine levels in blood 
was observed in rare disorders of the adrenal medulla, 
such as atrophy of the medulla caused by congenital ab-
sence of adrenal cortex and dopamine β-hydroxylase de-
ficiency (Fung et al., 2008).
Besides catecholamines, melanins (pigments providing 
protection against UV radiation) are also formed from 
tyrosine. In mammals, we distinguish two types of mela-
nins: phenyl-melanin (red-brown colour) and eumelanin 
(dark-brown colour). Because of the presence of tyrosi-
nase (EC 1.14.18.1), skin melanocytes have the ability to 
produce melanins. Tyrosinase catalyses the reaction of 
hydroxylation of tyrosine to l-DOPA and oxidation of 
l-DOPA to l-DOPA-quinone. This is a branch point of 
the pheno- and eumelanin synthesis pathway.
Melanoma is a result of the disorder of melanocyte 
function. In melanocytes with neoplastic changes, there 
is an increased synthesis of melanin. Melanins and their 
precursors occur in blood and in urine. The relation-
ship between the l-DOPA/l-tyrosine ratio and the 
clinical condition in patients was established based on 
the studies on biomarkers for melanoma. This ratio sig-
nificantly increases in patients with metastasis to local 
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lymph nodes and therefore may be useful in early de-
tection and effective treatment of the disease. In the 
case of patients without metastases, an elevated value 
of this ratio can indicate the worst prognosis. Other 
metabolites such as 5-S-cysteinyldopa (5-S-CD) of the 
pheomelanin pathway and, to a lower extent, 5-hy-
droxy-2-methoxy indole-2-carboxylic acid of the eume-
lanin pathway are used as markers of melanogenesis. 
However, the l-DOPA/l-tyrosine ratio seems to be 
a marker that is more sensitive and easier to evaluate 
(Figs. 1, 2) (Garnier et al., 2007).
In humans, tyrosine can be synthesized from phenyla-
lanine in liver and kidneys with the participation of phe-
nylalanine hydroxylase (EC 1.14.16.4; PAH). This proc-
ess is significantly impaired in chronic renal insufficiency 
(CRI), which results in a decrease in the tyrosine/pheny-
lalanine ratio in blood and tissues. In patients with CRI, 
oxidation stress occurs very often and results in the oc-
currence of oxidized tyrosine forms (chlorotyrosine and 
nitrotyrosine) in blood (Kopple, 2007).
THe signifiCanCe of TRypTopHan and iTs 
MeTaBoliTes in pHysiology and paTHology
Tryptophan is also a very important amino acid be-
cause two hormones, serotonin and melatonin, are syn-
thesized based on it. The first step in the synthesis of se-
rotonin is the synthesis of 5-hydroxytryptophan (5-HTP) 
due to tryptophan hydroxylase action (EC 1.14.16.4). 
Then, 5-HTP is converted into serotonin (5-hydroxy-
tryptamine — 5HT) with the participation of LAAD 
(Mendelsohn et. al., 2009; Thomas et al., 2010). Serotonin 
is a neurotransmitter that is responsible for regulation of 
cognitive functions of the brain. Therefore, any serious 
disturbance of serotonergic conduction results in psychi-
atric disorders related to disturbances of the mood, such 
as: depression, anxiety, schizophrenia, bipolar affective 
disorders. In some patients suffering from depression, 
changes in the level of 5-HT serotonin, which plays a 
significant role in mood regulation, can be observed; 
however, the low level of 5-HT may also result from 
figure 1. Tyrosine metabolites as components of pheomelanin and eumelanin pathways.
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lower concentration of tryptophan in the blood and its 
poor availability for the synthesis of this neurotransmit-
ter in the brain (Merens et. al., 2008).
From the clinical point of view, it is recommended to 
quantify the amount of serotonin. Because its content in 
the saliva is strongly correlated with its level in the cen-
tral nervous system (CNS), serotonin may be regarded in 
the future as a marker of neurodegenerative diseases. In-
terestingly, the content of serotonin is around two-times 
higher in the saliva of patients suffering from migraine 
than in the control population (Buczko et al., 2005).
In the pineal body, serotonin can be also used for 
the synthesis of another hormone, melatonin. Serotonin 
N-acetyltransferase (EC 2.3.1.87; SNAT) converts sero-
tonin to N-acetylserotonin (NAS), from which melatonin 
is directly formed (N-actetyl-5-methoxytryptamine) with 
the participation of hydroxyl-indol O-methyl transferase 
(HIOMT). Secretion of melatonin is a subject to daily 
fluctuations. It is synthesized and released at night, there-
fore it is called a night hormone (Banach et al., 2011).
However, the serotonin pathway is only in small part 
responsible for tryptophan transformation. A signifi-
cant majority, around 94 % of tryptophan, is degraded 
to kynurenine (KYN). This reaction is catalyzed by two 
enzymes: indoleamine 2,3-dioxygenase (EC 1.13.11.52; 
IDO) that occurs in kidneys, lungs, intestine, spleen, 
brain, epididymis, placenta, endocrine glands and in mac-
rophages/monocytes, and tryptophan 2,3-dioxygenase 
(EC 1.13.11.11; TDO), which is present only in liver. 
In the further stages of tryptophan transformation, a se-
ries of compounds (kynurenines) with specific biological 
properties are formed. The IDO is an inducible enzyme 
that is sensitive to proinflammatory cytokines, contrary 
to TDO that is more active when higher concentrations 
of TRY are present in the blood.
There is information in the published literature, which 
indicates a relationship between elevated activity of IDO 
and the occurrence of cardiovascular diseases in patients 
with terminal kidney insufficiency (end-stage renal dis-
ease; ESRD). The impairment of endothelium function 
in patients with ESRD is directly related to the accu-
mulation of kynurenines in blood plasma and elevated 
oxidation stress. Increase in the kynurenine/tryptophan 
ratio as a result of IDO activity, and the presence of ox-
idation stress markers can be a prognostic factor for the 
occurrence of a cardiovascular disease in patients with 
ESRD (Pawlak et al., 2009). It was also proved that an 
elevated level of metabolites of the kynurenic pathway 
(KP) and the increase in oxidation stress are significantly 
correlated with the presence of markers of vascular en-
figure 2. activity of aromatic amino acids (aaa) in biological systems. 
In liver and kidneys phenylalanine is converted to tyrosine with a contribution of phenylalanine hydroxylase (PAH). Tyrosine in turn is 
used in the synthesis of catecholamines (dopamine, epinephrine and norepinephrine) in the adrenal medulla and in the synthesis of 
pheomelanin and eumelanin in skin melanocytes, the first stage of which is l-DOPA formation. Elevated l-DOPA/l-Tyr index is observed 
in patients with malignant melanoma and metastases to local lymphoid nodules. Tyrosine is also an initial compound for the synthesis 
of thyroid gland hormones — thyroxine (T4) and triiodothyronine (T3). Other Tyr derivatives, like 3-Cl-D-Tyr or 3-N-D-Tyr, may be formed 
in conditions of oxidation, nitrification and chlorination stress. A neurotransmitter — serotonin (5-HT), which is also a melatonin precur-
sor in the pineal gland, is synthesised from tryptophan. The main way of TRY transformation is the kynurenine pathway, whose main 
enzymes include indoleamine 2,3-dioxygenase (IDO) present in brain and numerous peripheral tissues, and tryptophan 2,3-dioxygen-
ase (TDO) present in liver. Both these enzymes catalyze the same reaction of TRY conversion to kynurenine (KYN). IDO is an inducible 
enzyme subjected to activation in situations stressful for the organism, e.g. under the influence of proinflammatory cytokines. Elevated 
KYN/TRY index in patients with terminal renal insufficiency is a prognostic factor for the occurrence of heart and vascular complications.
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dothelium dysfunction, thrombomodulin (TM) and von 
Willebrand factor (vWF) (Pawlak et al., 2009). Increase 
in kynurenines and, related to it, a decrease in the level 
of tryptophan is the early indicator and a linking factor 
of such diseases as hypertension, chronic kidney insuffi-
ciency, diabetes, and cardiovascular complications. Stud-
ies performed by Koening (2010) demonstrated that a 
significant increase of the KYN/TRY ratio occurs also 
in dialyzed patients and is correlated with the increase 
in the concentration of neopterin. This proves the re-
lationship between enhanced degradation of tryptophan 
and inflammatory processes in patients (Koenig et al., 
2010). Recent studies by Pawlak et al. (2010) linked the 
increase in the concentration of metabolites of the kyn-
urenic pathway with an increased risk of the occurrence 
of Chronic Venous Disease (CVD) in patients with ter-
minal insufficiency of kidneys who received peritoneal 
dialysis. The increase in the concentration of KYN, kyn-
urenic acid (KYNA) and quinolinic acid (QA) was cor-
related with elevated levels of components of the hae-
mostatic system, such as tissue factor and its inhibitor, 
tissue and urokinase plasminogen activator, the plasmin/
antiplasmin complex and others. Some metabolites of 
kynurenine can be used as a prognostic factor of the 
occurrence of cardiovascular complications in patients 
receiving peritoneal dialysis (Pawlak et al., 2010). Inter-
estingly, the increase in IDO activity is induced mainly 
by interferon-γ (INF-γ), which is released during the 
inflammatory process. However, activation of IDO can 
be induced by other proinflammatory cytokines as well, 
such as interferon-α (IFN-α) and tumor necrotic factor 
(TNF-α). These compounds can enhance the INF-γ-
inducibility of IDO. A condition of chronic inflamma-
tion with a constant release of proinflammatory cytokines 
(PIC) occurs in people in the advanced age. Therefore, a 
relationship between increased activity of the kynurenic 
pathway, neuroendocrine disorders and the occurrence 
of metabolic syndrome in people in the advanced age is 
studied (Oxenkrug, 2010).
Increased level of kynurenines in saliva was estab-
lished in patients suffering from type 2 diabetes. How-
ever, this increased level is also related to the upregu-
lation of IDO by proinflammatory cytokines, because 
visceral adipose tissue, regarded as the main cause of 
insulin resistance, releases many biologically active sub-
stances, including TNF-α and IFN-γ. (Brandacher et 
al., 2007). The effect of the derivatives of tryptophan 
on the development of diabetes can proceed in two 
ways. Firstly, QA inhibits synthesis of proinsulin in the 
pancreas as well as its release from β cells. Moreover, 
xanthurenic acid (XA) forms a complex with insulin 
thereby insulin cannot bind to its receptor (Buczko et 
al., 2006). Studies on insulin resistance showed signifi-
cantly elevated activity of another enzyme of the kyn-
urenic pathway, ACMSD, in hepatocytes of rats with 
artificially induced diabetes (Sasaki et al., 2009). This is 
another element demonstrating a relationship between 
this particular disease entity and enhanced metabolism 
of tryptophan. Similarly to the interrelation between 
diabetes and changes in the oral cavity, the influence of 
tryptophan and its derivatives on the level of carbohy-
drates have a mutual character and needs more studies 
to be better known. The level of kynurenines increases 
rapidly in bacterial infections, which is related to stimu-
lation of the immunological system, release of proin-
flammatory cytokines and direct activation of IDO by 
bacterial lipopolysaccharides (LPS) in the oral cavity. 
Therefore, the assumption that the metabolism of tryp-
tophan is enhanced in inflammatory states of the gums 
and in parodontium diseases is totally justified (Buczko 
et al., 2005).
Quinolinic acid is also an agonist of the NMDA re-
ceptor (NMDAR), whose stimulation results in the in-
flux of calcium ions into cells followed by activation 
of proteases and generation of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) such as su-
peroxide radical anion (O2•–) and nitrogen oxide (NO). 
These processes can result in neuron damage as revealed 
in studies on the etiology of neurodegenerative diseases. 
As the agonist of the NMDA receptor, QA is an impor-
tant neurotoxic agent. In contrast to QA, KYNA, which 
is an antagonist of the NMDA receptor demonstrates 
neuroprotective action. The physiological level of QA 
does not have a negative effect on neurons; however, a 
slight increase in its concentration (an order of a few mi-
cromoles) is enough to cause damage. In patients with 
acquired immunodeficiency syndrome (AIDS), who also 
suffered from dementia, there was a 20-fold increase in 
QA concentration in cerebrospinal fluid (Stone et al., 
2003). A similar mechanism of neuron damage was ob-
served in patients with depression. As the study proved, 
lowering of 5-HT level in brain is not the only cause of 
mood disorders in this syndrome. Compounds that were 
mentioned earlier in the paper, which are generated dur-
ing the catabolism of tryptophan through the kynurenic 
pathway, also play a meaningful role. Increased activity 
of the hypothalamus – pituitary – adrenal glands axis 
together with increased glucocorticosteroids level accom-
pany depression as does general inflammatory state cou-
pled with activation of immunological cells and release 
of proinflammatory cytokines. These factors influence 
the induction of TDO (glucocorticosteroid) and IDO 
(PID). In women, the level of IDO activation is signifi-
cantly higher than in men, which means that the risk of 
depression is significantly higher in the female gender. 
Excessive activity of IDO and TDO results in a de-
crease in TRY concentration in the periphery and in the 
brain, limiting its availability for the synthesis of 5-HT. 
Kynurenines, when generated in excessive amounts, 
mostly demonstrate neurotoxic and neurodegenerative 
action. One example is the action of quinolinic acid as 
an agonist of the NMDA receptor. Another compound 
with high neurotoxic potential is 3-hydroxy-l-kynurenine 
(3-HKA) and its metabolite, 3-hydroxyanthranilic acid 
(3-HAA). In this case, neuron damage is caused by the 
action of free radicals: O2•–, hydroxyl radical (OH•) and 
superoxide (H2O2). Moreover, all three compounds im-
pair mitochondrial functions and finally result in a de-
crease in the efficacy of the electron transport chain and 
ATP production. Both the dysfunction of mitochondria 
and oxidation stress play an important role in the patho-
physiology of depression. QA, through its proinflamma-
tory properties, has an effect on the activation of immu-
nological cells of microglia and on the release of PID, 
which additionally enhance the activity of IDO. How-
ever, tryptophan and some of its degradation products, 
such as kynurenine, kynurenic acid and xanthurenic acid, 
due to anti-inflammatory properties, induce a negative 
feedback on cells of the immunological system, limiting 
production of proinflammatory cytokines and thereby 
the activity of IDO (Fig. 3).
Figure 3 shows that the (neuro)inflammation in de-
pression, which is characterized by an increased pro-
duction of interleukin-1β (IL-1)β, IL-6, tumor necro-
sis factor-α (TNFα) and interferon (IFN)γ, induces in-
doleamine 2,3-dioxygenase (IDO) in the blood and in 
Vol. 58       465Amino acids in biological systems
the brain. This results in reduced tryptophan (TRY) lev-
els and an increased production of tryptophan catabo-
lites (TRYCATs). It may be hypothesized that decreased 
tryptophan and increased TRYCAT levels may attenuate 
the inflammation-induced depressive behaviors.
There are assumptions that depression may be used as 
an early prognostic factor of Alzheimer’s disease. Both 
depression and dementia related to Alzheimer’s disease 
have a common background, which is the inflammatory 
state and activation of the kynurenic pathway (Maes et 
al., 2011). In Alzheimer’s disease, extracellular accumula-
tion of amyloid-β (Aβ) in the form of plaques, excessive 
phosphorylation of tau protein and formation of neuro-
fibrillary tangles (NFTs) was established. It is argued that 
Aβ activates Hortega cells and astrocytes by inducing 
inflammatory process and increased synthesis of toxic 
kynurenines. The action of 3-HKA and 3-HAA, through 
the release of ROS, can result in cell damage. Besides 
excitotoxicity induced by activation of the NMDA re-
ceptor and generation of oxidation stress, QA also has 
the ability to induce apoptosis in astrocytes and to timu-
late hyperphosphorylation of the tau protein, probably 
through lowering the activity of phosphatases. All these 
factors result in progressive neurodegeneration and de-
mentia characteristic for Alzheimer’s disease (Bonda et 
al., 2010). In addition, a relationship between the metab-
olites of tryptophan degradation and the occurrence of 
schizophrenia was also established. Kynurenic acid is an 
antagonist of the α7 nicotinic acetylcholine (α7-nAchR) 
and NMDA receptors. KYNA has neuroprotective ac-
tion. Through inhibition of the NMDA receptor, KYNA 
limits the phenomenon of cellular excitotoxicity mediat-
ed by this receptor. It also protects brain from hypoxia. 
Therefore, improper KYNA concentration can result in 
disturbances in cholinergic and glutaminergic transmis-
sion and thereby contribute to the onset of diseases with 
a neurological and psychiatric background. Inhibition of 
α7-nAchR through KYNA results in reduction of the 
glutamate level and a decrease in the extracellular con-
centration of dopamine. Lowering of the KYNA level 
results in an increase in dopamine concentration in stria-
tum (Rossi et al., 2008).
A hugely interesting and important issue is the partici-
pation of some tryptophan metabolites in carcinogenesis. 
Indolic derivatives of tryptophan, tryptamine (TA) and 
indole-3-acetic acid (IAA), are known as endogenous 
ligands which activate aryl hydrocarbon receptor; AhR. 
The transformed ligand — receptor complex is trans-
ported to the nucleus and, by binding to a specific DNA 
sequence it acts as a transcription factor enhancing ex-
pression of some genes including the gene encoding 
cytochrome P450 1A1 (CYP 1A1). CYP 1A1, together 
with other enzymes of the I and II stage of biotrans-
formation, can transform exogenous procancerogens into 
compounds that are able to directly damage DNA. In 
addition, tryptophan metabolites that are not carcinogens 
by themselves can promote a neoplastic process within 
the urinary bladder in the presence of carcinogenic sub-
stances such as 2-naphthylamine and 4-aminobiphenyl. 
Increase in metabolites of the kynurenic pathway, such 
as KN, 3-OHAA, XA and others was observed in urine 
in patients with urinary bladder cancer. This observation 
confirmed the accumulation of the kynurenic pathway 
metabolites in the urinary bladder. Synthesis of xanth-
urenic acid increases in states of vitamin B6 deficiency. 
A diet rich in tryptophan coupled with B6 deficiency in-
creases the risk of urinary bladder cancer. Tryptophan 
can be also metabolized to indole which is secreted to 
urine and acts as a carcinogenic agent (Chung & Gadu-
pudi, 2011). Moreover, a number of substances of a mu-
tagenic, genotoxic and carcinogenic character, such as 
phenolic and indolic compounds, can be formed from 
tryptophan and other aromatic amino acids remaining in 
the large intestine after bacterial degradation. Contribu-
tion of these compounds to the pathogenesis of large 
intestine cancer was proved (Nowak & Libudzisz, 2008). 
Studies performed by Suzuki et al., demonstrated an in-
crease in IDO activity in patients with lung cancer to-
gether with higher kynurenine concentration and lower 
tryptophan concentration in their sera. Elevated concen-
tration of KYN probably has an effect on the develop-
ment of immunological tolerance towards neoplastic cells 
through proliferation inhibition and induction of apop-
tosis of lymphocytes T. Additionally, it was established 
that increase in IDO activity is correlated with progres-
sion of the disease. However, there is no answer to the 
question how activation of IDO promotes lung cancer. 
The most probable scenario is participation of INF-γ 
that is endogenously released within cancer cells (Suzuki 
et al., 2010). Similar situation occurs in prostate cancer. 
Increased activity of IDO was detected in lymphatic ves-
sels of cancer patients and in neoplastic tissue in mice 
with artificially induced prostate cancer. The KYN/TRY 
ratio was significantly elevated in animals with detectable 
cancer. Increase in IDO activity, like in the above exam-
ple, was related with tumor-induced immunosupression. 
Lowering of IDO activity resulted in a delay in tumor 
growth (Källberg et al., 2010).
Another problem, which is gaining more and more 
attention recently, is oxidation stress. It was proved 
that tryptophan derivatives are among the strongest an-
tioxidants, but they do not react with all free radicals. 
figure 3. The TRyCaT pathway and indoleamine 2,3-dioxygen-
ase (ido) and their interconnections with peripheral and central 
immune, inflammatory, oxidation and nitrosative stress (io&ns) 
pathways.
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The 3-hydroxykynurenine, 3-hydroxyanthranilic acid 
and other kynurenines have the ability to scavenge O2•– 
(Brandacher et al., 2007). Activation of IDO during im-
munological reaction contributes to the control of the 
oxidation stress. However, NO and H2O2 inhibit IDO 
activity (Thomas & Stocker, 1999). On the other hand, 
as already mentioned in the paper, 3-HKA and 3-OHAA 
can generate free radicals in some conditions and there-
by evoke neuron damage during the course of neurode-
generative diseases.
As it was presented in this paper, aromatic amino 
acids and their derivatives exert many important func-
tions in the organism under normal physiological con-
ditions. Moreover, many of these compounds may be 
used as markers for identification of specific pathological 
states. Better knowledge of the metabolism of aromatic 
amino acids and the mechanisms of action of their me-
tabolites will contribute to the development of effective 
treatments for many disorders. However, it should not 
be forgotten that in some pathological conditions, these 
compounds could be also involved in the pathogenesis 
of many disease entities.
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